Gene expression and regulation, a key molecular mechanism driving human disease development, remains elusive, especially at early stages. The increasing amount of genomics data gathered from patients allows for better understanding of gene regulatory mechanisms that occur during disease development at a system level. However, integrating such a large amount of population data is still a challenging task. To address this, we developed an interpretable machine learning model, ECMarker, to predict gene expression biomarkers and regulatory networks specific for disease stages such as early cancer. In particular, ECMarker was built on the semi-restricted Boltzmann machine, a machine learning model with multiple hierarchical layers. This model allows one to directly model and prioritize gene interactions for the classification of clinical phenotypes, revealing potential gene regulatory networks (GRNs) for various cancer stages. We applied ECMarker to the gene expression data of non-small cell lung cancer (NSCLC) patients. Unlike the state-of-the-art machine learning methods designed for classification only, ECMarker not only achieved an accuracy > 85% for classification but also predicted a lung cancer GRN that is highly consistent with previous findings. Additionally, ECMarker has clear clinical interpretability as it is able to prioritize biomarker genes for early lung cancer that can predict survival rates of early cancer patients (p-value < 0.0035). Finally, we identified a number of drugs currently in clinical use for late stages (e.g., Navitoclax, Cyclopamine and Erlotinib) with effects on these early cancer biomarker genes, suggesting potential novel insights on early cancer medicine. ECMarker is also general purpose for other disease types and available as an open-source tool at https://github.com/daifengwanglab/tools.
epigenomics. This allows for studies of temporal dynamics in gene expression and regulation during cancer development and also allows for the systematic identification of stage-specific cancer biomarkers. Progress has been made in identification of some stage-specific molecular biomarkers of lung cancer, but systematic genome-wide analyses for identification of all potential early-stage biomarkers with predictive value for disease outcome are limited. For example, dysregulations in the epidermal growth factor receptor (EGFR, associated with sensitivity of lung cancers to the tyrosine kinase inhibitor gefitinib (Iressa) (Pao et al. 2004) , echinoderm microtubule-associated protein-like 4 (EML4), and anaplastic lymphoma kinase (ALK) are frequently involved in oncogenic transformation (Lindeman et al. 2013) . Additionally, v-raf murine sarcoma viral oncogene homologue B1 (BRAF) is a driver mutation gene in lung adenocarcinoma (Paik et al. 2011) .It remains challenging to integrate the large-scale data provided by human tumors to enable the discovery of genome-wide early cancer biomarkers and underlying GRNs. Although a challenging task, finding novel ways to integrate the large-scale data provided by human tumors would enable the discovery of genome-wide early cancer biomarkers and underlying GRNs.
Traditionally, correlation-based models have been used to select biomarker genes involved in cancer development; for example, 62 genes were uncovered in this way to distinguish between the early and late stages of clear cell renal cell carcinoma (ccRCC); (Rahimi and Gönen 2018) (Jagga and Gupta 2014) . However, correlation-based models only reveal linear relationships, whereas cancer development is a complex, nonlinear process. Thus, machine learning has emerged as a powerful tool to predict biomarkers for various cancer features related to clinical presentation and staging; this tool has been found to be of great help in the diagnosis and treatment of various diseases (Libbrecht and Noble 2015) . For example, (Statnikov, Wang and Aliferis 2008) applied random forests (RFs) and support vector machines (SVMs) to microarray data in order to aid in cancer diagnosis. (Xiao et al. 2018 ) constructed a multi-model ensemble approach to predict cancer in both normal conditions and tumor conditions. However, none of these studies revealed novel cancer mechanistic insights; these studies were limited to building an accurate classification model as a "black box" but lacked any biological or clinical interpretability from the box.
To address these challenges, we designed a novel, interpretable machine learning approach, ECMarker, that can be used to discover gene expression biomarkers in early disease stages such as early cancer. In particular, ECMarker embeds GRN structures into a hierarchical neural network model in order to classify early and late cancer patients according to their gene expression data. The prioritized genes and gene-gene interactions for early/late cancer stages revealed potential cancer stage-specific gene biomarkers and GRNs. Furthermore, we found drugs that are potentially associated with ECMarker's early cancer biomarkers with the goal of uncovering novel genomic medicine for early cancer development.
Materials and Methods

ECMarker, an interpretable machine learning framework to identify gene expression biomarkers and GRNs for cancer development and outcomes
We built an integrated, supervised machine learning framework, ECMarker, to identify the gene expression biomarkers for classifying cancer development stages and predicting clinical outcomes (Fig. 1) . ECMarker was built based on semi-restricted Boltzmann machine (SRBM) (Osindero and Hinton 2007b ) and including the following multi-step analysis:
Step 1. After feeding the gene expression data and various clinically relevant phenotypes of cancer patients (e.g., stages and survival) into the model, multiple feature selection methods were used to select a group of genes that potentially represent cancer development.
Step 2. Based on these genes, ECMarker identified the biomarker genes that classify the patients into stages of cancer, especially the early stages, and learned the connections between these genes that comprise imputed gene regulatory network.
Step 3. A survival analysis stratified the early cancer patients into the groups with different survival rates using the biomarker genes.
In addition to predicting cancer stages, ECMarker is also biologically and clinically interpretable First, the gene set enrichment analysis (GSEA; (Subramanian et al. 2005 ) was used with the potential biomarkers to reveal the underlying mechanisms of the biological processes and pathways of cancer development. In particular, various biological functions and pathways are impacted by the cancer gene expression changes that occur across stages, which are fundamentally controlled by GRNs. Thus, we used the structures of ECMarker to extract the GRNs that control the biomarker genes along with enriched functions and pathways. These biological explanations could provide a molecular, mechanistic understanding of cancer development. Furthermore, we predicted that certain drugs may significantly affect the biomarker genes or their regulatory factors, especially for early cancer stages, thus revealing potential stage-specific, genomic medicine targets and therapies.
The ECMarker classifier was built on a semi-restricted Boltzmann machine (SRBM) for biological interpretation
The ECMarker classifier was built on SRBM, which is a supervised learning probabilistic discriminative model. (Fig 1) 
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Ranking method based on the ECMarker classifier to prioritize cancer stage-specific biomarkers
The structure of the ECMarker classifier consists of nodes and weighted edges that link these nod (Fig. 1) . The weight values of the edges learned by ECMarker represent the strengths of interconnections between nodes. To identify early-stage biomarkers, we ranked all the absolu values of the weighted edges, linking each early-stage node to each hidden node. We selected the hidden nodes with the highest absolute weight values as the early stage-associated hidden nodes. F each gene, it connected to these ten "early" hidden nodes with weighted edges. Each gene connect to these ten "early" hidden nodes with weighted edges. We selected the highest absolute weight val as each gene's association score with the "early" hidden nodes. Then, we ranked all of the genes their association scores with the "early" hidden nodes and picked the top-ranking genes as early-sta biomarkers. Late-stage biomarkers were generated similarly. Firstly, we chose the top ten late-sta associated hidden nodes by ranking the absolute weight value between the late stage node and hidden nodes. Then based on strength of interactions between the ten "late" hidden nodes and ea gene, we selected the highest absolute weight value as this gene's association with late-stage hidd nodes. The genes were ranked according to highest associated with value and the top ranking gen are marked as the late-stage biomarkers.
Cancer gene expression and clinical datasets for building and testing ECMarker
We built and tested the ECMarker with two publicly accessible datasets. The Gentles2015 dataset (Gentles et al. 2015) consists of standardized gene expression data collected from 1103 non-small cell lung cancer (NSCLC) patients who had not received pre-biopsy treatment. Then, we grouped patients based on their TMN stages, with (I+IA+IB) as the early stage (N = 766) and II, III, and IV the late stages (N = 337) and divided the dataset into training and testing datasets. Lung adenocarcinoma (LUAD) is one of the most common subtypes of NSCLC (Herbst et al. 2018) .To demonstrate the utility of ECMarker in distinct subtypes of NSCLC, we downloaded LUAD datase from TCGA(The Cancer Genome Atlas Research et al. 2013), resulting in independent validation dataset TCGA-LUAD. After log2 transformation, each gene in the TCGA-LUAD dataset was standardized so that its mean expression was zero and its standard deviation was 1, as the same way 6 ene odes f the olute ten For ected value es by stage stage d all each idden genes V as o sets ay in Gentles2015. Furthermore, owing to the effects of some therapeutics on certain genes' expression levels (Zitvogel et al. 2008) , we focused on treatment-naïve tumors by excluding patients who received pharmaceutical (chemotherapy, targeted molecular therapy, immunotherapy), radiation, or surgical treatments, according to the TCGA-LUAD treatment annotation (Campbell et al. 2016 ) (The Cancer Genome Atlas Research et al. 2014), to avoid drug-induced gene expression profiles. Overall, we included 436 TCGA-LUAD patients as the independent validation dataset (N = 307 and N = 129 in the early and late stages, respectively). A summary on patient numbers of various stages is in S3 Table.
Feature extraction for ECMarker
The gene expression datasets were very high-dimensional and heterogeneous, especially at the tissue level (e.g., a wide variety of genes vs. limited sample size). In order to increase the interpretability and reduce the complexity and the training time of our model, we integrated extensive feature selection as an essential part before tuning our model. For this purpose, we tested multiple feature selection methods to reduce the dimensionality of gene expression data and input features for classification, including filter feature selection methods Pearson correlation, embedding methods LASSO, ridge regression, elastic net, wrapper methods, and Boruta (Kursa and Rudnicki 2010) algorithms using R functions (Friedman, Hastie and Tibshirani 2010) .
State-of-the-art classification methods
After feature selection, we compared the classification performance of ECMarker with several stateof-the-art classifiers, including an artificial neural network (ANN), random forests (RF), AdaBoostbased ensemble learning (ES), a support vector machine (SVM), naive Bayes (NB), and logistic regression (LR) toward discrimination between the early and late stages. These state-of-the-art classifiers could be implemented by the Scikit-Learn library in Python (Pedregosa et al. 2011 ).
Preprocessing for training the ECMarker classification model
First, we oversampled to balance the unbalanced dataset between early and late stages (69% earlystage patients vs. 31% late-stage patients). In particular, we used the oversampling method to replicate the sample from the minority class (late-stage patients) to balance the data. After oversampling, early and late-stage patients (1532 patients in total) had similar distributions in multiclinical features such as gender, stage, age. The stages of the individual cancer patients were used as output labels in classification. We implemented oversampling using R package ROSE (Lunardon, Menardi and Torelli 2014) . Second, we split the dataset into a training set (75%) and a test set (25%), while keeping some important features such as age, gender, and survival information in a similar distribution between them (S1 Table) . Finally, we binarized the gene expression data. The ECMarker model, based on the SRBM model, could only handle binary inputs. Therefore, we used the k-means clustering method in the BoolNet (Müssel, Hopfensitz and Kestler 2010) R package to binarize the real-value gene expression input data. For each gene, k-means clusterings were performed to split the expression data into two groups. After the centroid values were compared, the patients belonging to the group with the smaller centroid were set to 0, and the patients belonging to the greater centroid were set to 1.
Identification of drugs targeting biomarker genes predicted by ECMarker
We applied the gene-drug association model and analysis from PharmacoGx (Smirnov et al. 2016) , in which the association between the biomarker gene and drug sensitivity was modeled using linear regression. Because drug sensitivity is tissue-specific (Garnett et al. 2012 ) and batch variation exists, we adjusted the linear model of the drug-gene association for the tissue types and experimental batch.
indicates the lung cancer tumor source, and ‫ܤ‬ denotes the experimental batch.
ߚ was used to estimate the drug-gene association.
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and ‫ܩ‬ were scaled to access the relative importance of the different biomarker genes. Therefore, the drug with the highest absolute gene-drug association value (ߚ ) for each biomarker would be selected as the potential biomarker's drug.
Identification of pathways and functions associated with early and late cancer stages using ECMarker biomarker genes via enrichment analysis
To identify the pathways and functions related to early cancer, we also performed the enrichment analyses using ECMarker biomarker genes. In particular, given an ECMarker biomarker 's associated functions, and pathways. Then, we selected the top five ECMarker genes for the early cancer stage and identified their associated functions and pathways. The shared associated pathways and functions for at least three of these genes were defined as early cancer-associated pathways and functions. Similarly, we picked the top five ECMarker late-stage cancer-related genes and identified their associated pathways and functions. The significant overlapped functions and pathways for at least three of these genes were determined as late cancer-associated pathways and functions.
Results
Lung cancer gene expression biomarkers identified by the ECMarker model for classification of cancer stages
We applied ECMaker to the Gentles2015 dataset (see Methods) with the aim of predicting novel biomarker genes for lung cancer development and outcomes, especially for early-stage patients. ECMarker tested various feature selection methods such as LASSO, ridge regression, elastic net, and correlation and also prior biologically known gene sets related to cancer development as biological features, including epithelial-to-mesenchymal transition (EMT) signature genes (Byers et al. 2013) , lung cancer mutation genes, and transcription factor genes (Slowikowski 2016) (S2 Table) . Specifically, the best subset of potentially stage-correlated biomarkers can be identified with the highest classification accuracy. Using the top 200 cancer stage-related genes, selected as input by the ridge regression, as input, we found that ECMarker achieves the highest classification accuracy. Specifically, ECMarker had a classification accuracy of 0.835 (S2 Table) for the testing dataset. Then, we identified early and late biomarkers using the trained ECMarker model (Methods and Supplementary File 1) .
In order to gain biological insights into these stage-specific biomarkers at the functional level, we identified the enriched pathways and functions of the ECMarker biomarker genes associated with early and late cancer stages using GSEA MSigDB datasets (see Methods and Supplementary File 2). Figure 3 compares these enriched functions and pathways of the early and late stages. The early stage biomarkers are enriched in some lung cancer related pathways (for example, lung cancer poor survival or lung cancer KRAS), as well as pan-cancer functions/pathways and immunological pathways, which might reflect general early warning signs of cancer. The late stage biomarkers were enriched in more pathways and functions related with general tumour development, such as immunologic ones, or related to soft tissue tumours, myeloid cell development pathways associated with solid tumour development, and pathways related to primary immunodeficiency, differentiating T lymphocyte which might be linked to the cancer development process. These pathways and functions could be used to understand the molecular mechanisms of cancer progression at different stages. Also, the identification of these pathways and functions confirmed that ECMarker not only performs well in clinical outcome prediction but also provides mechanistic biological insights.
ECMarker biomarker genes predict clinical outcomes for early lung cancer
In addition to the biological functions associated with cancer stages, we also explored the relationships between gene biomarkers and clinical outcomes of cancer patients. In particular, using the hierarchical structure of ECMarker, we were able to identify the connections within the input gene set and reassign the cancer stages to each individual patient (see Methods). Thus, using the 25 early-stage biomarkers learned by ECMarker, we performed a survival analysis for early-stage patient groups clustered by predicted stages. Importantly, we found that the patient groups had significantly distinct survival rates, especially those at early cancer stages (i.e., ECMarker predicts early cancer survival rates). As shown in Figure 4 , the patients in the testing set that were reassigned to early stages had significantly different survival rates compared their survival rates in their original pathological stages. Moreover, we also found that more patients connected to the early stages in comparison with the pathological classification. This implies that the gene expression biomarkers identified by ECMarker were not only related to cancer stages but could also be used to predict clinical outcomes such as survival rates, particularly for early cancer patients. This suggests that ECMarker is clinically interpretable.
Hierarchy in the ECMarker reveals cancer functional genomics and regulatory networks across stages
Similar to other models, ECMarker can predict phenotypes from molecular data (e.g., gene expression to cancer stages), but understanding the biological mechanisms based on prediction model is still a challenging task. To this end, we endeavored to make ECMarker biologically interpretable.
In particular, we leveraged ECMarker to reveal the biological functions and pathways related to each cancer stage and provide mechanistic insights into the functional changes involved in cancer development. Then, we identified the enriched functions and pathways for stage-specific genes (see Fig. 3 ). Thus, we were able to show that ECMarker is biologically interpretable and able to reveal the functional modules connecting gene expression to phenotypes.
Furthermore, we pursued the elucidation of the molecular mechanisms that drive the functional connectivities, especially in terms of gene regulation. Gene expression, though complex for phenotypes, is controlled by gene regulatory mechanisms. In particular, various regulatory factors, such as transcription factors, control the expression of biomarker genes to coordinate cancer phenotypes so they do not behave randomly (i.e., forming a GRN). ECMarker has the capability to model gene interactions so that we could extract the weight value to describe the relationship of any pair of genes among the input genes. A larger absolute weight value indicated a stronger connection between genes. According to this standard, we could extract the learned GRN from any well-trained ECMarker classifier. Specifically, we identified stage-specific biomarkers and extracted the GRNs for these biomarkers to explore the changes from early to late cancer stages. Figure 2 shows the top 20 early and late-stage biomarkers. To uncover the hierarchy of transcription factors driving cancer stage development, we generated GRN representations connecting all the biomarkers, with separate representations for early and late stages of development. The highlighted TF-target connections indicated how interactions between biomarkers drive developmental progression.
Furthermore, we validated the regulatory linkages learned by ECMarker with previous predicted lung cancer regulatory networks (Mitra et al. 2014) . (Mitra et al. 2014 ) predicted highly confident regulatory relationships among TF regulation to target genes. Therefore, we inputted 123 genes that were listed in this paper (22 TF and 101 target genes) into ECMarker and compared the GRNs learned by ECMaker with their predicted results. ECMarker was able to learn 2222 (22 TF*101 target) pairs. We extracted 173 overlapped connected pairs matched with the predicted connected pair results from their study as overlapped TF-gene pair group (Group I), and other predicted connected pairs out of these 173 pairs as not overlapped TF-gene pair group (Group II). Then, we compared the absolute weight values between these two groups. We found that the absolute weight values of Group I were significantly higher than those of Group II (p<0.049), which suggests the consistency between ECMarker and (Mitra et al. 2014) . To further validate the connectivity results, we used the recent human TF-target database (Slowikowski 2016) to search for our predicted TFtarget pairs out of those 173 connected pairs in paper (Mitra et al. 2014) , and obtain a high-confident overlapped TF-gene pair group (Group III) . Then, we found that the absolute weights of Group III are even more significantly larger than Group I (p<0.0065, S1. Fig) . Therefore, the results of the present study suggested that the regulatory linkages found by ECMarker were highly consistent with previous predictions regarding GRNs involved in lung cancer. Moreover, the present results also suggested that ECMarker is biologically interpretable for revealing gene regulatory networks in the lung cancer.
Potential novel drugs for early cancer stages
The gene expression biomarkers and GRNs identified by ECMarker may provide target candidates for cancer medicine. Thus, we associated a variety of drugs with our stage-specific biomarker genes to find drugs with the potential to target specific stages of lung adenocarcinoma, which would enable different approaches to precision medicine. To produce an at-large list of potential drugs, we also included the genes co-expressed with our biomarker genes that were likely co-regulated by similar mechanisms (Methods). Thus, for each stage in NSCLC, we proceeded to identify a list of drugs that significantly correlate with the stage biomarker and co-expressed genes (e.g., IC50 value; see Supplementary File 3). For this purpose, we applied the gene-drug association model and analysis PharmacoGx (Smirnov et al. 2016) to large pharmacogenomic datasets such as the Genomics of Drug Sensitivity in Cancer database (GDSC database) ).
The GDSC database provides gene-drug sensitivity and response data for a variety of cancer types (i.e., cell lines). Underlying the power of our approach (see Methods), several known drugs for the treatment of late lung cancer stages were also predicted to have significant activity on our late-stage biomarkers; e.g., Sorafenib (Scagliotti et al. 2010 ) and BI-2536, a novel Plk-1 Inhibitor which could be used to treat stage IIIB/IV NSCLC patients undergoing surgery BI-2536 (Sebastian et al. 2010 ). In addition, Gefitinib, which has been used in a clinical trial to treat patients with EGFR mutations (Maemondo et al. 2010 ) could also improve progression-free survival in certain patients at advanced lung cancer stages. Interestingly, we also found that a few drugs in clinical use for late stages significantly correlate with our early stage biomarkers; e.g., Lapatinib (Ross et al. 2010 ), PD.0325901 (Haura et al. 2010) , and Sorafenib. Therefore, these drugs could potentially have effects on early cancer stages. Figure 5 shows the different prediction p-values between stage-specific genes for 30 prediction drugs. These results suggest that the gene expression biomarkers found by ECMarker are able to help identify potential drugs for early cancer treatment.
Comparison with state-of-the-art classification methods
A variety of state-of-the-art classification methods, such as ANN, SVM, RF, ES, LR, and NB (Methods), have been applied in cancer research for outcome detection and prediction. Even though these cancer applications have demonstrated effective and accurate performance, most of these methods lack biological and clinical interpretability, making it difficult to improve academic understanding of cancer progression using these methods. Therefore, we first compared our prediction performance with existing state-of-the-art methods; the results of this comparison are shown in S4 Table. Then, we selected some studies that made use of these methods and evaluated these works in the following aspects, computation performance, biological interpretability, and clinical interpretability demonstration in Table 2 . Table 2 . Comparison of ECMarker and previous studies using state-of-the-art classification methods
Method Biological application Interpretability
RF, SVM
Undertook a methodologically comprehensive comparison of random forests and support vector machines for microarray-based cancer classification (Statnikov et al. 2008) .
Used a large number of datasets to compare two classifiers but failed to explore the biological insights of the best performance classifier after identifying this model.
KNN, SVM, RF, ANN
Demonstrated a new strategy that applied deep learning to an ensemble approach that incorporated different machine learning models for cancer prediction with gene data selected by differential gene expression analysis (Xiao et al. 2018 ).
Trained the model as a black box after reaching high accuracy, but did not further explore GRNs, functions, or pathways to better understand cancer mechanisms.
ES
Performed a comparison of single supervised machine learning and ensemble methods in classifying cancerous gene expression data and presented some theoretical explanations for the performance of ensemble methods (Tan and Gilbert 2003) .
Improved understanding of the correlations between gene expression profiles and cancer developmental stages but did not focus on the far more important aspects of theoretical, biological, and clinical explanations.
LR
Proposed an improved sparse logistic regression method to identify discriminatory biomarker genes based on gene expression data in cancer classification (Cawley and Talbot 2006) .
Sufficiently evaluated the computational performance of various methods in multicancer datasets but lacked biologically or clinically interpretable analysis of the selected biomarker genes.
ANN
Trained ANNs using the gene expression signatures of small, round blue-cell tumors (SRBCTs) to classify cancers into specific diagnostic categories (Statnikov et al. 2005) .
After training the high-accuracy ANN model, the authors extracted 96 genes that were highly relevant to cancer. Although the authors discussed the identification of genes specific to cancer with implications for biology and therapy, they did not conduct a GRN analysis or detection of gene-gene interactions.
Discussion
In this paper, we developed a machine learning approach as well as a computational framework, ECMarker, to identify gene expression biomarkers for various stages of cancer development.
ECMarker is both biologically and clinically interpretable for the discovery of gene expression biomarkers. In particular, ECMarker simultaneously predicts the underlying GRNs for these biomarkers and thus possesses biological interpretability, which state-of-the-art machine learning models typically lack. We applied ECMarker to individual gene expression data for lung cancer, the leading cause of cancer-related deaths, and identified a set of novel biomarker genes classifying cancer stages. We found that these biomarkers significantly predict patients' survival rates, especially at the early stage, and can also be linked to potential novel drugs; this reveals the clinical interpretability of our approach. The predicted biomarker genes comprise novel molecular candidates for early cancer diagnosis and detection, and the GRNs could potentially guide future experimental validations for early cancer mechanisms and treatments. Although this study applied ECMarker lung cancer data specifically, ECMarker is a general-purpose method and can therefore be applied for other disease types including neurodevelopmental disorders ).
This study demonstrated that we are able to build machine learning models that are biologically interpretable. This was our first round of attempts to address the lack of interpretability and translation of machine learning applications in biology and biomedicine. Given that cancer phenotypes are driven by a variety of multi-omic mechanisms, including transcriptomics, epigenomics, metabolomics, etc., we expect to develop advanced machine learning approaches that can reveal interactions across multi-omics relating to phenotypes in the near future. In particular, by integrating genotyping data, we aim to build a deeper hierarchical model, similar to deep neural network models , to predict genotype-phenotype relationships and use intermediate connectivities and structures inside the model to reveal all possible molecular mechanisms from genotype to phenotype.
The present study focused on gene expression data at the individual tissue level. However, the cancer tissues consist of different cell types with various fitness and mutational profiles (Saadatpour et al. 2015) . The continuous development of single-cell genomic and transcriptomic analyses for cancer research will enable us to explore how single cells contribute to cancer tissue expression and eventually affect phenotypes (e.g., single-cell deconvolution to estimate various cell fractions).
Integrating single-cell data into machine learning modelling and drug association analysis might uncover novel biological mechanisms and targetable key regulators for the advancement of precision cancer medicine.
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D.W. conceived and designed the project. T.J. and D.W. performed data processing and analyses. T.J., F.T. and D.W. wrote the manuscript. All authors read and approved the final manuscript. Fig. 1 ECMarker, an interpretable machine learning framework for the identification of gene expression biomarkers of cancer stages and the prediction of clinical outcomes. ECMarker was built on a hierarchical neural network model, semi-restricted Boltzmann machine (sRBM). The gene expression data of cancer patients was inputted to predict their cancer stages. ECMarker has three layers: (1) the input layer-gene, (2) the hidden layer, and (3) the output layer-cancer stage. In addition to predicting cancer stages, ECMarker is also biologically and clinically interpretable for (A) identifying the gene expression biomarkers and regulatory networks of each stage; (B) reporting the associated biological functions and pathways for each stage; (C) predicting clinical outcomes such as / survival rates, especially for early cancer patients; and (D) discovering novel drugs that could potentially affect early cancer. Red and blue represent early and late stages, respectively.
Figures
Fig. 2
ECMarker identifies cancer stage-specific GRNs for lung cancer. The GRN connects TF genes to target genes. The left network is for early-stage cancer; the right network is for late-stage cancer. Nodes are ECMarker expression biomarker genes for early-stage (blue) and late-stage (red) cancer. The grey nodes are the common biomarker genes between the early and late stages. Node size is proportional to the correlation coefficient between expression levels and stages of the gene across patients. Genes are connected with high connection weights from ECMarker. The edge width of two genes is proportional to the connection weight predicted by ECMarker.
Fig. 3 ECMarker genes reveal biological functions and pathways associated with cancer stages.
Select pathways and functions are found for early (left) and late (right) stages in lung cancer by gene set enrichment analysis (GSEA) for ECMarker biomarker genes. The x-axis represents the number of genes in the associated pathways/functions (y-axis). Black highlights immunological pathways. A complete list of lung cancer stage-associated functions and pathways is available in Supplement File 2.
Common Genes Early-stage Genes Common Genes
Correlation with cancer stage Early Stage Late Stage Fig. 4 ECMarker genes enable the prediction of early cancer survival rates. Early lung cancer patients were clustered into three major groups based on the top 25 ECMarker biomarker genes for early-stage cancer. These biomarker genes were found using the Gentles2015 dataset (Gentles et al. 2015) . A Kaplan-Meier analysis showed that the clustering groups using ECMarker biomarkers had significantly different survival rates (p < 0.0035), as shown in the left panel. In addition, application of these biomarker genes to an independent cohort, TCGA-LUAD (The Cancer Genome Atlas Research et al. 2013), showed that early-stage patients also had significantly different survival rates (p < 0.065), as shown in the right panel.
Fig. 5
ECMarker genes can be used to discover novel, potentially effective drugs for early lung cancer. Using early stage-specific and late stage-specific gene groups to predict which drugs might be effective. The heatmap shows the gene-drug association matrix that ECMarker predicted for lung cancer. ECMarker (x-axis) predicted 19 early-stage biomarker genes (blue), 18 late-stage biomarker genes (red), and 30 potentially effective drugs (y-axis). The color bar in the range of [0,1] corresponds to the gene-drug association value. A higher gene-drug association value indicates greater drug sensitivity. Out of 37 associated gene-drug pairs (estimate coefficient > 0.917), 21 pairs have been supported by previous clinical studies. 
